相关实验视频

Updated: May 6, 2026

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

将基因组和蛋白质组特征与大脑粉样蛋白负担联系起来:来自GR@ACE/DEGESCO的见解

Raquel Puerta^1,2, Itziar de Rojas^1,3, Pablo García-González^1,3

¹Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, C/ Marquès de Sentmenat, 57, 08029, Barcelona, Spain.

Functional & integrative genomics

|March 26, 2025

概括

这项研究结合了脑脊液 (CSF) 的全基因组关联研究 (GWAS) 和正子发射断层扫描 (PET) 的粉样蛋白测量,以发现阿尔茨海默病 (AD) 的遗传风险因素. 结果确定了新的遗传位置和生物途径,涉及到AD的病变发生.

科学领域:

神经遗传学神经遗传学
生物标志物生物标志物
阿尔茨海默氏症疾病研究研究

背景情况:

阿尔茨海默病 (AD) 具有重要的遗传成分,但许多风险因素仍未确定.
通过脑脊液 (CSF) 和正子发射断层扫描 (PET) 测量的粉样蛋白病理,是AD的关键替代品.
整合遗传和蛋白质组数据可以阐明AD的潜在生物机制.

研究的目的:

通过结合全基因组关联研究 (GWAS) 的粉样内基因型,识别阿尔茨海默病的新型遗传风险因素.
探索与粉症相关的遗传位置和CSF蛋白质组之间的关系.
通过综合分析,揭示参与AD病变的生物学途径.

主要方法:

在6个队伍中对CSF Aβ42和PET粉样蛋白测量进行了全基因组关联研究 (meta-GWAS).
利用SOMAscan蛋白质组学来分析CSF蛋白质组,并识别与粉症相关的蛋白质.
对重叠的遗传和蛋白质组命中进行了丰富分析,并将结果与大型公共数据集进行了比较.

主要成果:

在rs429358-APOE位点观察到全基因组显著性,确定了九个暗示性命中.
复制了APOE位点,并确定了与AD相关的新型GADL1位点.
1,387个FDR显著的SOMAscan蛋白与CSF Aβ42水平相关,与GWAS位置的重叠很小.
丰富分析揭示了氨基粉症,血膜成分,突触生理学和精神障碍之间的联系.

结论:

将CSF和PET粉样GWAS与CSF蛋白质组分析结合起来,可以有效地识别AD遗传风险因素.
这种综合方法揭示了驱动粉样蛋白调动和AD病理的分子机制.
这项研究突出了新的途径和基因,包括GADL1,与阿尔茨海默病有关.

关键词:

Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 在CSF的生物标志物中.在GWAS中,GWAS就是GWAS.皮特断层扫描 PET断层扫描蛋白质组是蛋白质组的组成部分.

更多相关视频

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Published on: April 28, 2022

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...